These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 34109145)

  • 1. Cost-Effectiveness Analysis of 23-Valent Pneumococcal Polysaccharide Vaccine Program for the Elderly Aged 60 Years or Older in Shanghai, China.
    Sun X; Tang Y; Ma X; Guo X; Huang Z; Ren J; Qiu J; Jiang H; Lu Y
    Front Public Health; 2021; 9():647725. PubMed ID: 34109145
    [No Abstract]   [Full Text] [Related]  

  • 2. Economic Evaluation of Immunisation Programme of 23-Valent Pneumococcal Polysaccharide Vaccine and the Inclusion of 13-Valent Pneumococcal Conjugate Vaccine in the List for Single-Dose Subsidy to the Elderly in Japan.
    Hoshi SL; Kondo M; Okubo I
    PLoS One; 2015; 10(10):e0139140. PubMed ID: 26444287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of a 23-valent pneumococcal polysaccharide vaccine immunization programme for the elderly in Shanghai, China.
    Zhao D; Gai Tobe R; Cui M; He J; Wu B
    Vaccine; 2016 Dec; 34(50):6158-6165. PubMed ID: 27838068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness and Health Benefits of Pediatric 23-valent Pneumococcal Polysaccharide Vaccine, 7-valent Pneumococcal Conjugate Vaccine and Forecasting 13-valent Pneumococcal Conjugate Vaccine in China.
    Mo X; Gai Tobe R; Liu X; Mori R
    Pediatr Infect Dis J; 2016 Nov; 35(11):e353-e361. PubMed ID: 27753771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retrospective cost-effectiveness of the 23-valent pneumococcal polysaccharide vaccination program in Australia.
    Chen C; Beutels P; Wood J; Menzies R; MacIntyre CR; McIntyre P; Newall AT
    Vaccine; 2018 Oct; 36(42):6307-6313. PubMed ID: 30213457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A cost-effectiveness analysis of revaccination and catch-up strategies with the 23-valent pneumococcal polysaccharide vaccine (PPV23) in older adults in Japan.
    Jiang Y; Yang X; Taniguchi K; Petigara T; Abe M
    J Med Econ; 2018 Jul; 21(7):687-697. PubMed ID: 29723081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Health economic evaluation of a 23 value pneumococcal polysaccharide vaccination pilot programme among elderly chronic obstructive pulmonary disease patients in China].
    Qiu YP; Zhao K; Li X; Shi LW; Guo WD; Qi XR; Sui BY; Zhou RM
    Zhonghua Yu Fang Yi Xue Za Zhi; 2016 Dec; 50(12):1074-1078. PubMed ID: 28057111
    [No Abstract]   [Full Text] [Related]  

  • 8. Cost-effectiveness of 13-valent pneumococcal conjugate vaccine (PCV13) in older Australians.
    Dirmesropian S; Wood JG; MacIntyre CR; Beutels P; McIntyre P; Menzies R; Reyes JF; Chen C; Newall AT
    Vaccine; 2017 Aug; 35(34):4307-4314. PubMed ID: 28693751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of pneumococcal vaccination strategies for the elderly in Korea.
    Heo JY; Seo YB; Choi WS; Lee J; Noh JY; Jeong HW; Kim WJ; Kim MJ; Lee HY; Song JY
    PLoS One; 2017; 12(5):e0177342. PubMed ID: 28498857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of dual influenza and pneumococcal vaccination among the elderly in Shenzhen, China.
    Chen D; Ye Z; Pi Z; Mizukami S; Aoyagi K; Jiang Y
    Vaccine; 2021 Apr; 39(16):2237-2245. PubMed ID: 33757667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines.
    Tyo KR; Rosen MM; Zeng W; Yap M; Pwee KH; Ang LW; Shepard DS
    Vaccine; 2011 Sep; 29(38):6686-94. PubMed ID: 21745516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cost effectiveness of vaccination against pneumococcal bacteremia in the elderly: the results in Belgium].
    De Graeve D; Verhaegen J; Ament A; Baltussen R
    Acta Clin Belg; 2000; 55(5):257-65. PubMed ID: 11109640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness, immunogenicity and safety of 23-valent pneumococcal polysaccharide vaccine revaccinations in the elderly: a systematic review.
    Remschmidt C; Harder T; Wichmann O; Bogdan C; Falkenhorst G
    BMC Infect Dis; 2016 Nov; 16(1):711. PubMed ID: 27887596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of pneumococcal vaccination for elderly in Sweden.
    Wolff E; Storsaeter J; Örtqvist Å; Naucler P; Larsson S; Lepp T; Roth A
    Vaccine; 2020 Jul; 38(32):4988-4995. PubMed ID: 32536548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccination Program in Chronic Obstructive Pulmonary Disease Patients Aged 50+ Years in Spain.
    Rodríguez González-Moro JM; Menéndez R; Campins M; Lwoff N; Oyagüez I; Echave M; Rejas J; Antoñanzas F
    Clin Drug Investig; 2016 Jan; 36(1):41-53. PubMed ID: 26547199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines.
    Rozenbaum MH; Sanders EA; van Hoek AJ; Jansen AG; van der Ende A; van den Dobbelsteen G; Rodenburg GD; Hak E; Postma MJ
    BMJ; 2010 Jun; 340():c2509. PubMed ID: 20519267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimating the cost-effectiveness of an infant 13-valent pneumococcal conjugate vaccine national immunization program in China.
    Shen K; Wasserman M; Liu D; Yang YH; Yang J; Guzauskas GF; Wang BCM; Hilton B; Farkouh R
    PLoS One; 2018; 13(7):e0201245. PubMed ID: 30044865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of pneumococcal and influenza vaccination standing order programs.
    Lin CJ; Zimmerman RK; Smith KJ
    Am J Manag Care; 2013 Jan; 19(1):e30-7. PubMed ID: 23379777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cost-effectiveness of using pneumococcal conjugate vaccine (PCV13) versus pneumococcal polysaccharide vaccine (PPSV23), in South African adults.
    Feldman C; Dlamini SK; Madhi SA; Meiring S; von Gottberg A; de Beer JC; de Necker M; Stander MP
    PLoS One; 2020; 15(1):e0227945. PubMed ID: 31995597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cost-effectiveness of starting 23-valent pneumococcal polysaccharide vaccine and influenza vaccination at 50 vs. 65 years: A comparative modelling study.
    Ding H; Huang J; Ngai CH; Sun Q; Kwok KO; Wang HH; Chong M; Wong MC
    Vaccine; 2022 Feb; 40(9):1282-1288. PubMed ID: 35094867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.